Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Solitary Fibrous Tumors | 1 | 2023 | 67 | 0.830 |
Why?
|
| Hypoglycemia | 1 | 2023 | 883 | 0.520 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 504 | 0.330 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 1361 | 0.320 |
Why?
|
| Telemedicine | 1 | 2024 | 2998 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2022 | 2448 | 0.240 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 1612 | 0.240 |
Why?
|
| Neoplasms | 5 | 2024 | 22019 | 0.210 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3759 | 0.210 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 1744 | 0.190 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 429 | 0.180 |
Why?
|
| Medical Oncology | 2 | 2024 | 2311 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 4491 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 4883 | 0.140 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 525 | 0.130 |
Why?
|
| Mutation | 7 | 2024 | 29877 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 6311 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 332 | 0.110 |
Why?
|
| Alleles | 3 | 2022 | 6897 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 611 | 0.110 |
Why?
|
| Trifluoperazine | 1 | 2012 | 37 | 0.100 |
Why?
|
| Cross Infection | 1 | 2021 | 1434 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 1790 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 487 | 0.090 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 475 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 435 | 0.090 |
Why?
|
| Pyrroles | 1 | 2017 | 1135 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4111 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 2012 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5214 | 0.080 |
Why?
|
| Palliative Care | 1 | 2024 | 3606 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2012 | 1755 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 13238 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2803 | 0.070 |
Why?
|
| Pandemics | 2 | 2024 | 8609 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2012 | 1886 | 0.070 |
Why?
|
| Computational Biology | 1 | 2018 | 3505 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2012 | 3604 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2012 | 3605 | 0.060 |
Why?
|
| Quinazolines | 1 | 2012 | 1362 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5635 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2017 | 2996 | 0.060 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 4871 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3584 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 11123 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 6218 | 0.050 |
Why?
|
| Humans | 12 | 2024 | 759255 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9374 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13621 | 0.050 |
Why?
|
| Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
| Prognosis | 2 | 2018 | 29561 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 2866 | 0.040 |
Why?
|
| Censuses | 1 | 2021 | 201 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 12580 | 0.040 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 538 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 7595 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 17750 | 0.030 |
Why?
|
| Oncogenes | 1 | 2022 | 1221 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 8491 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2015 | 115 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16871 | 0.030 |
Why?
|
| Middle Aged | 4 | 2024 | 219653 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20461 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 659 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2017 | 335 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 3615 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 671 | 0.030 |
Why?
|
| Female | 6 | 2024 | 390240 | 0.030 |
Why?
|
| Physician's Role | 1 | 2020 | 920 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2017 | 23362 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 504 | 0.030 |
Why?
|
| Data Mining | 1 | 2017 | 550 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 64879 | 0.020 |
Why?
|
| Diarrhea | 1 | 2017 | 1340 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2015 | 858 | 0.020 |
Why?
|
| Inpatients | 1 | 2021 | 2580 | 0.020 |
Why?
|
| Male | 3 | 2023 | 358719 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2020 | 2510 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 81138 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2017 | 1378 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 6813 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5194 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 4716 | 0.020 |
Why?
|
| Animals | 2 | 2015 | 167838 | 0.010 |
Why?
|
| Genomics | 1 | 2017 | 5775 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 58867 | 0.010 |
Why?
|
| Aged | 2 | 2024 | 168617 | 0.010 |
Why?
|
| Adult | 2 | 2024 | 219390 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41247 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39216 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 54204 | 0.010 |
Why?
|
Concepts
(91)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_